Buserelin is a synthetic hormone agent used in settings where suppressing natural sex hormone production is the clinical goal. Patients and clinicians researching it often want to know what conditions it addresses and what trial evidence supports its use.
Key takeaways
- Buserelin has an approved drug label and has reached the highest level of clinical development (max phase 4).
- It is registered across 43 clinical trials, spanning oncology and reproductive medicine.
- Trial data in the sample include completed and active Phase 3 studies in prostate cancer and ovarian stimulation.
- No FAERS adverse event reports were available in this dataset to summarize.
- Its PubChem entry (CID 50225) describes a large peptide structure, consistent with its hormone-agonist class.
What the evidence shows
Buserelin is linked to 43 registered clinical trials. Among the sampled studies, a completed Phase 3 trial evaluated buserelin alongside hormone therapy, radiation, and an androgen synthesis inhibitor in patients with high-risk prostate cancer. A related Phase 3 trial, still active and not recruiting, is testing treatment intensity tailored to genetic risk scores in the same patient population. A separate completed Phase 3 trial examined buserelin within dual ovarian stimulation protocols for patients with poor ovarian response, reflecting its use in reproductive medicine alongside its oncology applications.
Reported side effects
No adverse event report data were available for buserelin in this dataset, so a summary of reported reactions cannot be provided here.